Edwards Lifesciences Corporation (EW)
USD 75.65
(0.63%)
USD 75.65
(0.63%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 9.36 Billion USD | 12.91% |
| 2022 | 8.29 Billion USD | -2.47% |
| 2021 | 8.5 Billion USD | 17.49% |
| 2020 | 7.23 Billion USD | 11.54% |
| 2019 | 6.48 Billion USD | 21.87% |
| 2018 | 5.32 Billion USD | -6.54% |
| 2017 | 5.69 Billion USD | 26.31% |
| 2016 | 4.51 Billion USD | 11.1% |
| 2015 | 4.05 Billion USD | 15.18% |
| 2014 | 3.52 Billion USD | 29.35% |
| 2013 | 2.72 Billion USD | 22.65% |
| 2012 | 2.22 Billion USD | 12.17% |
| 2011 | 1.98 Billion USD | 12.07% |
| 2010 | 1.76 Billion USD | 9.39% |
| 2009 | 1.61 Billion USD | 15.38% |
| 2008 | 1.4 Billion USD | 4.1% |
| 2007 | 1.34 Billion USD | 7.88% |
| 2006 | 1.24 Billion USD | 1.44% |
| 2005 | 1.22 Billion USD | 10.46% |
| 2004 | 1.11 Billion USD | 1.03% |
| 2003 | 1.1 Billion USD | 9.24% |
| 2002 | 1 Billion USD | 3.62% |
| 2001 | 973 Million USD | -10.57% |
| 2000 | 1.08 Billion USD | -24.29% |
| 1999 | 1.43 Billion USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 10.09 Billion USD | 3.73% |
| 2024 Q1 | 9.73 Billion USD | 3.98% |
| 2023 Q4 | 9.36 Billion USD | -0.08% |
| 2023 Q1 | 8.65 Billion USD | 4.33% |
| 2023 Q2 | 9 Billion USD | 4.08% |
| 2023 Q3 | 9.37 Billion USD | 4.07% |
| 2023 FY | 9.36 Billion USD | 12.91% |
| 2022 Q4 | 8.29 Billion USD | -4.0% |
| 2022 Q3 | 8.63 Billion USD | 2.53% |
| 2022 Q1 | 8.41 Billion USD | -0.97% |
| 2022 Q2 | 8.42 Billion USD | 0.06% |
| 2022 FY | 8.29 Billion USD | -2.47% |
| 2021 Q2 | 7.66 Billion USD | 6.22% |
| 2021 Q4 | 8.5 Billion USD | 4.19% |
| 2021 FY | 8.5 Billion USD | 17.49% |
| 2021 Q1 | 7.21 Billion USD | -0.32% |
| 2021 Q3 | 8.16 Billion USD | 6.5% |
| 2020 Q1 | 6.07 Billion USD | -6.35% |
| 2020 Q2 | 6.42 Billion USD | 5.73% |
| 2020 FY | 7.23 Billion USD | 11.54% |
| 2020 Q4 | 7.23 Billion USD | 6.42% |
| 2020 Q3 | 6.8 Billion USD | 5.86% |
| 2019 Q1 | 5.46 Billion USD | 2.73% |
| 2019 Q3 | 5.96 Billion USD | 7.05% |
| 2019 FY | 6.48 Billion USD | 21.87% |
| 2019 Q4 | 6.48 Billion USD | 8.75% |
| 2019 Q2 | 5.57 Billion USD | 1.91% |
| 2018 Q1 | 5.82 Billion USD | 2.26% |
| 2018 FY | 5.32 Billion USD | -6.54% |
| 2018 Q4 | 5.32 Billion USD | -10.65% |
| 2018 Q2 | 5.68 Billion USD | -2.39% |
| 2018 Q3 | 5.95 Billion USD | 4.79% |
| 2017 Q2 | 5.13 Billion USD | 7.49% |
| 2017 FY | 5.69 Billion USD | 26.31% |
| 2017 Q4 | 5.69 Billion USD | 3.79% |
| 2017 Q3 | 5.48 Billion USD | 6.81% |
| 2017 Q1 | 4.78 Billion USD | 6.0% |
| 2016 Q3 | 4.33 Billion USD | 7.1% |
| 2016 Q1 | 3.85 Billion USD | -5.06% |
| 2016 Q4 | 4.51 Billion USD | 3.94% |
| 2016 FY | 4.51 Billion USD | 11.1% |
| 2016 Q2 | 4.05 Billion USD | 5.13% |
| 2015 Q3 | 3.87 Billion USD | 7.44% |
| 2015 Q1 | 3.48 Billion USD | -1.02% |
| 2015 FY | 4.05 Billion USD | 15.18% |
| 2015 Q2 | 3.6 Billion USD | 3.44% |
| 2015 Q4 | 4.05 Billion USD | 4.71% |
| 2014 Q3 | 3.35 Billion USD | 0.7% |
| 2014 Q1 | 2.65 Billion USD | -2.68% |
| 2014 Q2 | 3.32 Billion USD | 25.45% |
| 2014 FY | 3.52 Billion USD | 29.35% |
| 2014 Q4 | 3.52 Billion USD | 5.2% |
| 2013 Q2 | 2.33 Billion USD | 1.88% |
| 2013 Q3 | 2.53 Billion USD | 8.16% |
| 2013 Q4 | 2.72 Billion USD | 7.67% |
| 2013 FY | 2.72 Billion USD | 22.65% |
| 2013 Q1 | 2.29 Billion USD | 3.38% |
| 2012 Q4 | 2.22 Billion USD | 1.17% |
| 2012 FY | 2.22 Billion USD | 12.17% |
| 2012 Q3 | 2.19 Billion USD | 5.82% |
| 2012 Q2 | 2.07 Billion USD | 3.54% |
| 2012 Q1 | 2 Billion USD | 1.2% |
| 2011 FY | 1.98 Billion USD | 12.07% |
| 2011 Q4 | 1.98 Billion USD | -0.12% |
| 2011 Q3 | 1.98 Billion USD | -0.97% |
| 2011 Q2 | 2 Billion USD | 3.69% |
| 2011 Q1 | 1.93 Billion USD | 9.27% |
| 2010 FY | 1.76 Billion USD | 9.39% |
| 2010 Q2 | 1.64 Billion USD | 2.34% |
| 2010 Q4 | 1.76 Billion USD | 2.42% |
| 2010 Q3 | 1.72 Billion USD | 5.09% |
| 2010 Q1 | 1.6 Billion USD | -0.69% |
| 2009 Q4 | 1.61 Billion USD | 1.73% |
| 2009 Q3 | 1.58 Billion USD | 8.39% |
| 2009 Q1 | 1.35 Billion USD | -2.95% |
| 2009 Q2 | 1.46 Billion USD | 7.82% |
| 2009 FY | 1.61 Billion USD | 15.38% |
| 2008 FY | 1.4 Billion USD | 4.1% |
| 2008 Q1 | 1.31 Billion USD | -2.59% |
| 2008 Q2 | 1.34 Billion USD | 2.9% |
| 2008 Q3 | 1.38 Billion USD | 2.44% |
| 2008 Q4 | 1.4 Billion USD | 1.38% |
| 2007 Q4 | 1.34 Billion USD | 3.49% |
| 2007 Q1 | 1.24 Billion USD | 0.19% |
| 2007 Q2 | 1.25 Billion USD | 0.21% |
| 2007 Q3 | 1.29 Billion USD | 3.83% |
| 2007 FY | 1.34 Billion USD | 7.88% |
| 2006 Q3 | 1.24 Billion USD | -1.5% |
| 2006 FY | 1.24 Billion USD | 1.44% |
| 2006 Q4 | 1.24 Billion USD | 0.52% |
| 2006 Q2 | 1.25 Billion USD | 1.55% |
| 2006 Q1 | 1.24 Billion USD | 0.89% |
| 2005 Q2 | 1.15 Billion USD | 2.47% |
| 2005 Q4 | 1.22 Billion USD | 7.34% |
| 2005 Q3 | 1.14 Billion USD | -0.5% |
| 2005 FY | 1.22 Billion USD | 10.46% |
| 2005 Q1 | 1.12 Billion USD | 0.93% |
| 2004 Q1 | 1.1 Billion USD | 0.22% |
| 2004 Q2 | 1.08 Billion USD | -1.29% |
| 2004 Q3 | 1.07 Billion USD | -1.62% |
| 2004 Q4 | 1.11 Billion USD | 3.81% |
| 2004 FY | 1.11 Billion USD | 1.03% |
| 2003 Q4 | 1.1 Billion USD | 2.86% |
| 2003 Q1 | 1.03 Billion USD | 2.75% |
| 2003 Q2 | 1.07 Billion USD | 4.23% |
| 2003 FY | 1.1 Billion USD | 9.24% |
| 2003 Q3 | 1.07 Billion USD | -0.82% |
| 2002 Q3 | 918.4 Million USD | -6.6% |
| 2002 Q4 | 1 Billion USD | 9.78% |
| 2002 Q2 | 983.3 Million USD | 1.85% |
| 2002 Q1 | 965.4 Million USD | -0.78% |
| 2002 FY | 1 Billion USD | 3.62% |
| 2001 FY | 973 Million USD | -10.57% |
| 2001 Q1 | 1.1 Billion USD | 1.37% |
| 2001 Q4 | 973 Million USD | 1.4% |
| 2001 Q3 | 959.6 Million USD | -4.73% |
| 2001 Q2 | 1 Billion USD | -8.68% |
| 2000 FY | 1.08 Billion USD | -24.29% |
| 2000 Q4 | 1.08 Billion USD | -1.61% |
| 2000 Q3 | 1.1 Billion USD | -1.53% |
| 2000 Q2 | 1.12 Billion USD | -18.68% |
| 2000 Q1 | 1.38 Billion USD | -3.9% |
| 1999 Q4 | 1.43 Billion USD | 0.0% |
| 1999 FY | 1.43 Billion USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Abbott Laboratories | 73.21 Billion USD | 87.211% |
| Allurion Technologies Inc. | 71.71 Million USD | -12956.671% |
| Artivion, Inc. | 792.39 Million USD | -1081.63% |
| Avanos Medical, Inc. | 1.69 Billion USD | -453.25% |
| Butterfly Network, Inc. | 304.27 Million USD | -2977.226% |
| Butterfly Network, Inc. | 304.27 Million USD | -2977.226% |
| Bio-Rad Laboratories, Inc. | 12.29 Billion USD | 23.871% |
| Boston Scientific Corporation | 35.13 Billion USD | 73.352% |
| CONMED Corporation | 2.3 Billion USD | -307.092% |
| Paragon 28, Inc. | 340.69 Million USD | -2648.232% |
| Glaukos Corporation | 940.41 Million USD | -895.647% |
| Globus Medical, Inc. | 5.08 Billion USD | -84.095% |
| Inspire Medical Systems, Inc. | 676.81 Million USD | -1283.429% |
| Integer Holdings Corporation | 2.94 Billion USD | -218.189% |
| Medtronic plc | 89.98 Billion USD | 89.594% |
| Myomo, Inc. | 14.58 Million USD | -64112.573% |
| Nevro Corp. | 635.71 Million USD | -1372.866% |
| Owlet, Inc. | 44.12 Million USD | -21120.679% |
| Penumbra, Inc. | 1.55 Billion USD | -501.63% |
| Vicarious Surgical Inc. | 119.86 Million USD | -7711.52% |
| Smith & Nephew plc | 9.98 Billion USD | 6.246% |
| STERIS plc | 11.06 Billion USD | 15.37% |
| Stryker Corporation | 39.91 Billion USD | 76.54% |
| Vapotherm, Inc. | 77.61 Million USD | -11963.337% |
| Zimmer Biomet Holdings, Inc. | 21.49 Billion USD | 56.444% |